Kirkstall has developed Quasi Vivo™, an advanced interconnected cell culture flow system, engineered to provide in vivo-like conditions for cell growth. Its patented technology is used by researchers in academia and drug development and provides a way to model the behaviour of multiple human organs interconnected by a system that mimics the flow of blood in the body. It can significantly increase the physiological relevance of research, helping users generate more accurate models and greatly improve confidence in the validity of their results.
Braveheart owns 64.67% of the issued share capital in Kirkstall and also provides significant management resource to the company. As we own more than 50% of Kirkstall we are deemed by the auditors to have control of the business and so consolidate the company accounts into Braveheart’s group accounts.
Find out more about Kirkstall Limited